Brentjens, Renier Joseph

Publications

Sort by

Co-Author Network

selected publications

Low toxicity and favorable overall survival in relapsed/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplant. Bone marrow transplantation. 2020 Academic Article GET IT
Times cited: 10
Excessive Costimulation Leads to Dysfunction of Adoptively Transferred T Cells. Cancer immunology research. 2020 Academic Article GET IT
Times cited: 16
Optimization of T-cell Receptor-Modified T Cells for Cancer Therapy. Cancer immunology research. 2020 Academic Article GET IT
Times cited: 14
Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. Blood advances. 2020 Academic Article GET IT
Times cited: 81
CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma. Blood. 2019 Academic Article GET IT
Times cited: 49
Tumors evading CARs-the chase is on. Nature medicine. 2018 Comment GET IT
Times cited: 27
Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository Experience. Molecular therapy. Methods & clinical development. 2018 Academic Article GET IT
Times cited: 21
Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nature biotechnology. 2018 Academic Article GET IT
Times cited: 446
Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2018 Academic Article GET IT
Times cited: 147
Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia. Cancer discovery. 2018 Academic Article GET IT
Times cited: 478
Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System. Cell reports. 2018 Academic Article GET IT
Times cited: 195
Building a CAR Garage: Preparing for the Delivery of Commercial CAR T Cell Products at Memorial Sloan Kettering Cancer Center. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2018 Review GET IT
Times cited: 55
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. The New England journal of medicine. 2018 Academic Article GET IT
Times cited: 1524
Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib. Cancer cell. 2017 Academic Article GET IT
Times cited: 137
Emerging Role of CAR T Cells in Non-Hodgkin's Lymphoma. Journal of the National Comprehensive Cancer Network : JNCCN. 2017 Review GET IT
Times cited: 16
Immunotherapy: Hiding in plain sight: immune escape in the era of targeted T-cell-based immunotherapies. Nature reviews. Clinical oncology. 2017 Review GET IT
Times cited: 7
Development of CAR T cells designed to improve antitumor efficacy and safety. Pharmacology & therapeutics. 2017 Review GET IT
Times cited: 81
At the Bench: Chimeric antigen receptor (CAR) T cell therapy for the treatment of B cell malignancies. Journal of leukocyte biology. 2016 Review GET IT
Times cited: 7
CD19-Targeted CAR T cells as novel cancer immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia. Clinical advances in hematology & oncology : H&O. 2016 Review GET IT
Times cited: 80
Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells. Cell. 2016 Academic Article GET IT
Times cited: 172
Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells. Cytotherapy. 2016 Review GET IT
Times cited: 74
CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date. Blood. 2016 Review GET IT
Times cited: 286
Medical management of side effects related to CAR T cell therapy in hematologic malignancies. Expert review of hematology. 2016 Editorial Article GET IT
Times cited: 34
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nature reviews. Clinical oncology. 2016 Academic Article GET IT
Times cited: 175
Toxicity and management in CAR T-cell therapy. Molecular therapy oncolytics. 2016 Review GET IT
Times cited: 578
Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy. Biochemical Society transactions. 2016 Review GET IT
Times cited: 148
Driving CAR T-cells forward. Nature reviews. Clinical oncology. 2016 Review GET IT
Times cited: 421
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nature reviews. Clinical oncology. 2016 Review GET IT
Times cited: 702
Are chimeric antigen receptor T cells ready for prime time?. Clinical advances in hematology & oncology : H&O. 2016 Academic Article GET IT
Times cited: 3
Novel immunotherapies in lymphoid malignancies. Nature reviews. Clinical oncology. 2015 Review GET IT
Times cited: 195
Chimeric antigen receptor T cells for cancer immunotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Comment GET IT
Times cited: 49
A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer. Journal of translational medicine. 2015 Academic Article GET IT
Times cited: 197
IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. Oncoimmunology. 2015 Academic Article GET IT
Times cited: 106
Are all chimeric antigen receptors created equal?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Comment GET IT
Times cited: 19
Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression. Molecular therapy : the journal of the American Society of Gene Therapy. 2015 Academic Article GET IT
Times cited: 181
CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?. Immunotherapy. 2015 Review GET IT
Times cited: 31
CD19 CAR Therapy for Acute Lymphoblastic Leukemia. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2015 Review GET IT
Times cited: 41
CD19-Targeted T Cells for Hematologic Malignancies: Clinical Experience to Date. Cancer journal (Sudbury, Mass.). 2015 Review GET IT
Times cited: 24
The Tol2 transposon system mediates the genetic engineering of T-cells with CD19-specific chimeric antigen receptors for B-cell malignancies. Gene therapy. 2014 Academic Article GET IT
Times cited: 22
High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation. Blood. 2014 Academic Article GET IT
Times cited: 86
T-cell immunotherapy: looking forward. Molecular therapy : the journal of the American Society of Gene Therapy. 2014 Conference Paper GET IT
Times cited: 55
Acute myeloid leukemia arising from a donor derived premalignant hematopoietic clone: A possible mechanism for the origin of leukemia in donor cells. Leukemia research reports. 2014 Academic Article GET IT
Times cited: 15
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Science translational medicine. 2014 Academic Article GET IT
Times cited: 1836
CD28z CARs and armored CARs. Cancer journal (Sudbury, Mass.). 2014 Review GET IT
Times cited: 80
Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies. International journal of hematology. 2013 Review GET IT
Times cited: 87
CD19 target-engineered T-cells accumulate at tumor lesions in human B-cell lymphoma xenograft mouse models. Biochemical and biophysical research communications. 2013 Academic Article GET IT
Times cited: 13
The basic principles of chimeric antigen receptor design. Cancer discovery. 2013 Review GET IT
Times cited: 928
Chimeric antigen receptor therapy for chronic lymphocytic leukemia: what are the challenges?. Hematology/oncology clinics of North America. 2013 Review GET IT
Times cited: 13
Engineered human embryonic stem cell-derived lymphocytes to study in vivo trafficking and immunotherapy. Stem cells and development. 2013 Academic Article GET IT
Times cited: 20
CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Science translational medicine. 2013 Academic Article GET IT
Times cited: 1557
Immunotherapies in CLL. Advances in experimental medicine and biology. 2013 Review GET IT
Times cited: 7
In vivo imaging enables high resolution preclinical trials on patients' leukemia cells growing in mice. PloS one. 2012 Academic Article GET IT
Times cited: 38
How do CARs work?: Early insights from recent clinical studies targeting CD19. Oncoimmunology. 2012 Academic Article GET IT
Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. The journal of gene medicine. 2012 Review GET IT
Times cited: 185
CARs and cancers: questions and answers. Blood. 2012 Comment GET IT
Times cited: 12
Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood. 2012 Academic Article GET IT
Times cited: 497
Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen. Hematology. American Society of Hematology. Education Program. 2012 Review GET IT
Times cited: 66
Cellular therapies in acute lymphoblastic leukemia. Hematology/oncology clinics of North America. 2011 Review GET IT
Times cited: 12
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011 Academic Article GET IT
Times cited: 1031
In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy. Cancer research. 2011 Academic Article GET IT
Times cited: 78
CARs on track in the clinic. Molecular therapy : the journal of the American Society of Gene Therapy. 2011 Conference Paper GET IT
Times cited: 108
Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Academic Article GET IT
Times cited: 113
Adoptive immunotherapy for B-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells. Discovery medicine. 2010 Academic Article GET IT
Times cited: 46
Adoptive T cell immunotherapy strategies for the treatment of patients with ovarian cancer. Discovery medicine. 2010 Review GET IT
Times cited: 21
Cellular therapies in acute lymphoblastic leukemia. Current opinion in molecular therapeutics. 2009 Review GET IT
Times cited: 8
The promise and potential pitfalls of chimeric antigen receptors. Current opinion in immunology. 2009 Review GET IT
Times cited: 376
Sensitive in vivo imaging of T cells using a membrane-bound Gaussia princeps luciferase. Nature medicine. 2009 Academic Article GET IT
Times cited: 106
Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. Journal of immunotherapy (Hagerstown, Md. : 1997). 2009 Academic Article GET IT
Times cited: 236
Retroviral transduction of murine primary T lymphocytes. Methods in molecular biology (Clifton, N.J.). 2009 Academic Article GET IT
Times cited: 31
Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 62
Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors. Nature biotechnology. 2008 Academic Article GET IT
Times cited: 100
Multifactorial optimization of gammaretroviral gene transfer into human T lymphocytes for clinical application. Human gene therapy. 2007 Academic Article GET IT
Times cited: 30
T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nature medicine. 2007 Academic Article GET IT
Times cited: 227
Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Academic Article GET IT
Times cited: 352
Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2007 Academic Article GET IT
Times cited: 415
Novel approaches to the immunotherapy of B-cell malignancies: An update. Current hematologic malignancy reports. 2006 Review GET IT
Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Academic Article GET IT
Times cited: 142
Targeted elimination of prostate cancer by genetically directed human T lymphocytes. Cancer research. 2005 Academic Article GET IT
Times cited: 100
Novel approaches to immunotherapy for B-cell malignancies. Current hematology reports. 2005 Review GET IT
Times cited: 6
Novel approaches to immunotherapy for B-cell malignancies. Current oncology reports. 2004 Review GET IT
Times cited: 4
Novel strategies for cancer therapy: the potential of genetically modified T lymphocytes. Current hematology reports. 2004 Review GET IT
Times cited: 17
Somatic cell engineering and the immunotherapy of leukemias and lymphomas. Advances in pharmacology (San Diego, Calif.). 2004 Review GET IT
Times cited: 4
Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nature medicine. 2003 Academic Article GET IT
Times cited: 519
Targeting tumours with genetically enhanced T lymphocytes. Nature reviews. Cancer. 2003 Review GET IT
Times cited: 415
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nature biotechnology. 2002 Academic Article GET IT
Times cited: 726
Islet cell tumors of the pancreas: the medical oncologist's perspective. The Surgical clinics of North America. 2001 Review GET IT
Times cited: 134
Fine tangled pili expressed by Haemophilus ducreyi are a novel class of pili. Journal of bacteriology. 1996 Academic Article GET IT
Times cited: 64
Haemophilus ducreyi adheres to human keratinocytes. Microbial pathogenesis. 1994 Academic Article GET IT
Times cited: 25

more ...

less ...

Background

education and training

M.D., Ph.D., State University of New York at Buffalo, School of Medicine and Biomedical Sciences 1996
M.A., State University of New York at Buffalo 1994
B.A., Davidson College 1989

VIVO Weill Cornell Medical College

Renier Joseph Brentjens Adjunct Professor of Pharmacology (Courtesy)

Publications

selected publications

Background

education and training

Contact

full name

primary email

Phone

Publications

selected publications

Background

education and training

Contact

full name

primary email